Our Technology

Adjuvance’s technology is based on the modular synthesis of QS-21, a leading vaccine adjuvant and a component of the GSK AS01 vaccine. Development of this modular approach, allowed for rationale interrogation of structural analogues, which were screen using QS-21 as the comparator. Several improved analogues were discovered with TQL1055 being the best. We now use this modular approach to efficiently manufacture both adjuvants, SAPONEX for products currently tied to QS-21, and TQL1055 for products that would benefit from the best adjuvant.

Competitive Advantage – SAPONEX and TQL1055